Product Development Pipeline

Torque is developing a new class of Deep-Primed™ T cell therapeutics for the treatment of cancer. Our immuno-oncology strategy is to:

  1. prime and activate T cells to target multiple tumor antigens, and
  2. tether immune-stimulatory drugs to the surface of these multi-target T cells to direct immune activation in the tumor microenvironment
  3. using a proprietary technology platform, without genetic engineering, for a high margin of safety.

In hematologic cancers, our new class of immune cell therapeutics has the potential to improve on the initial success of single-target CAR-T therapeutics with expanded efficacy, and also move cell therapy treatment out of the hospital with a high margin of safety. For solid tumors, Deep-Primed T cells have the potential to enable efficacy against tumors with heterogeneous antigens protected by hostile microenvironments, which are not readily addressable with the first generation of immune cell therapies.

We believe there is a significant opportunity to dramatically expand cancer cures, particularly for solid tumors, using Deep-Primed T cells with high cell doses, administered with repeat doses to drive deep and persistent clinical responses.


Torque Product Development Pipeline

Our lead product candidate——TRQ-1501 (Deep IL-15 Primed T Cells)—is in Phase 1/2 clinical trials for solid tumors and hematologic cancers. In this study, the Deep-Primed T cells are being administered in an outpatient setting without any preconditioning regimen. Patients are receiving repeat doses of cells, in contrast to current cellular immuno-oncology treatment regimens that are limited to single-dose treatment and require both lymphodepleting preconditioning chemotherapy and hospitalization to monitor and manage toxicities. In preclinical studies, TRQ-1501 demonstrated increased T cell proliferation, engraftment, and tumor cell killing, including the potential to improve on preconditioning regimens.

We are also developing Deep IL-12 Primed T Cells and small-molecule Deep TLR Primed T Cells to target both adaptive and innate immunity, to amplify the immune response for durability and memory. In addition, we are pursuing several approaches to develop Deep Checkpoint Inhibitors.

Policy on Expanded Access to Torque Investigational Medications >


Back to Top